MedTrace Logo

IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers

NCT04584515 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2021-08-24

No results posted yet for this study

Summary

A Phase I, Open-label, Fixed-Sequence Study to Evaluate the Effect of Multiple-dose Itraconazole or Rifampicin Capsules on the Single-dose PK Profiles of IMP4297 Capsules in Healthy Subjects

Conditions

Interventions

DRUG

IMP4297 40 mg

IMP4297 40 mg: IMP4297 alone, Itraconazole + IMP4297

DRUG

IMP4297 100 mg

IMP4297 100 mg: IMP4297 alone, Rifampin + IMP4297

Sponsors & Collaborators

  • Impact Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Pingsheng Xu · Xiangya Hospital of Central South University

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-02
Primary Completion
2021-03-08
Completion
2021-05-27

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04584515 on ClinicalTrials.gov